



# USAMRDC Good News Story



## U.S. Army Medical Research and Development Command

### *Another Victory for Army-Backed, Next-Gen Blood Vessel Product*

- A collection of bioengineered Human Acellular Vessels (HAVs) were implanted into a retired veteran suffering from vascular disease at Walter Reed National Military Medical Center on July 2, 2019.
- HAVs are an off-the-shelf, bioengineered blood vessel product designed to repair and reconstruct vascular injuries in order to restore blood flow to extremities. The procedure on July 2 was the *second-ever* HAV surgical graft performed under a compassionate-use Investigational New Drug application approved by the FDA.
- The HAV is developed by Humacyte, Inc., and stands as the lead candidate for the U.S. Army Extremity Injury Repair–Vascular (EIR-V) acquisition program.
- The HAV is financially supported in part by the Medical Technology Enterprise Consortium (MTEC); a USAMRDC-affiliated national biomedical technology consortium charged with developing solutions to protect the Warfighter.
- The *first-ever* HAV graft was *also* performed at Walter Reed National Military Medical Center back in May 2019.



*Clockwise from bottom left: Close-up of an HAV (courtesy Humacyte); Surgeons prepare HAVs for use (Courtesy Humacyte); official WRNMMC logo; official MTEC logo.*

**OUTCOME:** By supporting new and emerging medical technology, the USAMRDC helps develop products that have the potential to significantly improve the immediate and long-term care of the Warfighter and the U.S. public.